Main Objective: Is treatment with temozolomide efficacious? Treatment is considered to be efficacious if the probability for no event within the first 6 months after diagnosis” is not markedly inferior in comparison with the corresponding 6-months EFS-rates of the historical control group which was defined from patients of cohorts HIT-GBM-C and –D. That means that the probability for no event within the first 6 months after diagnosis” is not = 46% for patients with a pontine tumour and not = 53% for patients with a non-pontine tumour. (6-months EFS-rates of historical control group from HIT-GBM-C+D were: 51% for patients with a pontine tumour, 58% for patients with a non-pontine tumour).;<br>                Secondary Objective: 1.Do the overall survival (OS) and event-free survival (EFS) of patients of the HIT-HGG-2008 trial differ from the OS / EFS of patients of the historical control groups (HIT-GBM-C and -D)?<br>                2. Does the HIT-HGG-2008 treatment lead to different toxicity rates in comparison to the historical control group (HIT-GBM-C and -D)?<br>                3. Has the methylation of the O6-MGMT gene promoter within the primary tumour an influence on the EFS?<br>                4. Do the clinical parameters (tumour location (ICDO classification), tumour grading and centrally reviewed histology, extent of tumour resection, genetic syndromes, secondary malignancies, age at diagnosis, gender, and relapse treatment within HIT-HGG-2008) have an influence on EFS or OS?<br>                5.  Is there an association between these clinical parameters and the affiliation to one of the two patient groups HIT-HGG-2008 and HIT-GBM-C/-D?<br>            ;<br>                Primary end point(s): Event-status 6 months after diagnosis: event / no event (i.e. by magnetic resonance imaging). An event” is defined as<br><br>                •progression/relapse of disease<br>                •diagnosis of a secondary malignancy<br>                •death of any cause.<br><br>                We assume that each patient will be observed at least 6 months after diagnosis.<br>